Patent 11053251 was granted and assigned to Prometheus Biosciences on July, 2021 by the United States Patent and Trademark Office.
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.